Saturday, July 20, 2024

Intellasia East Asia News – Merck’s COVID-19 pill active against Omicron in lab studies

Must Read


Merck & Co Inc (MRK.N) and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading Omicron variant.

The data evaluated the antiviral activity of molnupiravir and other COVID-19 antiviral agents against COVID-19 variants of concern. Molnupiravir is yet to be studied against Omicron in human studies, the companies said.

Molnupiravir and a rival oral pill from Pfiser Inc (PFE.N) were authorised in the United States in December and are considered as important tools against Omicron.

Pfiser said in December lab data suggested its drug Paxlovid retained its effectiveness against Omicron.

Merck said earlier this month its pill has a mechanism that can work against Omicron and any other variant.

Molnupiravir has been authorised for use in more than 10 countries, including the United States, United Kingdom and Japan.

https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-covid-19-pill-effective-against-omicron-lab-studies-2022-01-28/

 

Category: Health


Print This Post


- Advertisement -spot_img
- Advertisement -spot_img

Latest News

Plastic Waste Conversion: Study finds how plastic waste can be converted to electronic devices

DELAWARE: The University of Delaware and the Argonne National Laboratory have developed a chemical process that converts Styrofoam...
- Advertisement -spot_img

More Articles Like This

- Advertisement -spot_img